Download PDF
Pneumologie 2003; 57(1): 34-41
DOI: 10.1055/s-2003-36635
Projektdarstellung
© Georg Thieme Verlag Stuttgart · New York

CAPNetz - Kompetenznetzwerk ambulant erworbene Pneumonie: Strukturen und Ziele

CAPNet-Network of Competence for Community Acquired Pneumonia: Structures and AimsT.  Welte1 , R.  Marre1 , N.  Suttorp1
  • 1CAPNetz Geschäftsstelle, Ulm
Ein besonderer Dank gilt Herrn Dr. med. Gunther Boenisch, der als freier Medizinjournalist wesentlich zur Fertigstellung dieses Artikels beigetragen hat.
Further Information

Publication History

Eingereicht: 21. Oktober 2002

Angenommen: 29. Oktober 2002

Publication Date:
15 January 2003 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die ambulant erworbene Pneumonie (Community Acquired Pneumonia/CAP) ist auch in Deutschland eine Erkrankung mit hoher Morbidität und Mortalität. Trotz der Bedeutung der CAP fehlen hier zu Lande zuverlässige Daten zum Erregerspektrum, zur Resistenzsituation der Erreger, zum Verlauf der Erkrankung ebenso wie evidenzbasierte Therapieempfehlungen. Auch die Grundlagenforschung in diesem Bereich ist stark verbesserungswürdig. Das Bundesministerium für Bildung und Forschung (BMBF) hat diese Defizite erkannt und fördert deshalb seit 2002 CAPNetz, das Kompetenznetzwerk ambulant erworbene Pneumonie.

Abstract

Community Acquired Pneumonia (CAP) is a disease with high morbidity and mortality in Germany. Apart from the importance of CAP, no reliably data is available about infective germs, resistance of germs, course of the disease, or evidence based treatment. Also basic research should be improved in this field. The German State Ministry for Research (BMBF) has recognised these deficits and supports CAPNet, the network of competence for Community Acquired Pneumonia since 2002.

Literatur

  • 1 Osler W. Lobar pneumonia. In: The principles and practice of of medicine. Edinburgh & London: Young J, Pentland 1901: 126-129
    Google Scholar
  • 2 Chanock R M, Dienes L, Eaton M D. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism.  Science. 1963;  140 662-669
    PubMedGoogle Scholar
  • 3 Farr B M, Kaiser D L, Harrison B DW. et al . Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features.  Thorax. 1989;  44 1031-1035
    CrossrefPubMedGoogle Scholar
  • 4 Tew J, Calenoff L, Berlin B S. Bacterial or nonbacterial pneumonia: accuracy of radiographic diagnosis.  Radiology. 1977;  124 607-612
    PubMedGoogle Scholar
  • 5 Woodhead M, Torres A. Definition and classification of community-acquired and nosocomial pneumonias.  Eur Respir Mon. 1997;  3 1-12
    PubMedGoogle Scholar
  • 6 Escamilla R, Hermant C. Pneumonia in immunocompromised patients.  Eur Respir Mon. 1997;  3 189-208
    PubMedGoogle Scholar
  • 7 Pingleton S K, Fagon J Y, Leeper K V. Patient selection for clinical investigation of ventilator-associated pneumonia.  Chest. 1992;  102 (Suppl. 1) 557S-564S
    PubMedGoogle Scholar
  • 8 ERS Task Force Report . Guidelines for management of adult community-acquired lower respiratory tract infections.  Eur Respir J. 1998;  11 986-991
    CrossrefPubMedGoogle Scholar
  • 9 Bartlett J G, Breiman R F, Mandell L A. et al . Community-acquired pneumonia in adults: Guidelines for management.  Clin Infect Dis. 1998;  26 811-838
    CrossrefPubMedGoogle Scholar
  • 10 Lopez A D, Murray C C. The global burden of disease.  Nat Med. 1998;  4 1241-1243
    CrossrefPubMedGoogle Scholar
  • 11 Center for Disease Control and Prevention . Premature deaths, monthly mortality and monthly physician contacts - United States.  MMWR Morb Mortal Wkly Rep. 1997;  46 556
    PubMedGoogle Scholar
  • 12 Marston B J, Plouffe J F, File T M. et al . Incidence of community acquired pneumonia requiring hospitalizations.  Arch Intern Med. 1997;  157 1509-1518
    PubMedGoogle Scholar
  • 13 Niederman M S, McCombs J S, Unger A N. et al . The cost of treating community-acquired pneumonia.  Clin Ther. 1998;  20 820-837
    CrossrefPubMedGoogle Scholar
  • 14 Fine M J, Auble T E, Yealy D M. et al . A prediction rule to identify low-risk patients with community acquired pneumonia.  N Engl J Med. 1997;  336 243-250
    CrossrefPubMedGoogle Scholar
  • 15 Marrie T J, Lau C Y, Wheeler S L. et al . A controlled trial of a critical pathway for treatment of community-acquired pneumonia.  JAMA. 2000;  283 749-755
    CrossrefPubMedGoogle Scholar
  • 16 Fine M J, Smith M A, Carson C A. et al . Prognosis and outcome of patients with community acquired pneumonia.  JAMA. 1996;  275 134-141
    CrossrefPubMedGoogle Scholar
  • 17 Dean N C, Silver M P, Bateman K A. et al . Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia.  Am J Med. 2001;  110 451-457
    CrossrefPubMedGoogle Scholar
  • 18 Moroney J F, Fiore A E, Harrison L H. et al . Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.  Clin Infect Dis. 2001;  33 797-805
    CrossrefPubMedGoogle Scholar
  • 19 Reinert R R, Al-Lahham A, Lemperle M. et al . Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.  J Antimicrob Chemother. 2002;  49 61-68
    CrossrefPubMedGoogle Scholar
  • 20 Priest P, Yudkin P, McNulty C. Antibacterial prescribing and antibacterial resistance in English general practice: cross sectional study.  BMJ. 2001;  323 1037-1041
    CrossrefPubMedGoogle Scholar
  • 21 Ross J J, Worthington M G, Gorbach S L. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  347 65-67
    CrossrefPubMedGoogle Scholar
  • 22 Marrie T J, Peeling R W, Fine M J. Ambulatory patients with community acquired pneumonia, the frequency of atypical agents and clinical course.  Am J Med. 1996;  101 508-515
    CrossrefPubMedGoogle Scholar

Geschäftsstelle CAPNetz

Albert-Einstein-Allee 47

89069 Ulm

      >